Asceneuron discovers and develops groundbreaking therapeutics for neurodegenerative disorders with high unmet medical needs: orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
Asceneuron Welcomes Barbara Angehrn Pavik as New CEO
Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth
-
Event
Asceneuron to attend BIO International Convention in Boston
The Asceneuron team will attend the BIO International Convention to be held June 5-8 in Boston, MA.
-
Event
Asceneuron will present at AD/PD 2023
The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from...
-
Event
Asceneuron to attend Bio-Europe Spring event
Asceneuron's CEO Dirk Beher will attend the Bio Europe Spring partnering event held on March 20-22, 2023 in Basel, Switzerland.
-
Press releases
Ferrer acquires worldwide rights to ASN90, exclusively to treat PSP
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)
-
Event
Asceneuron at the Annual Biotech in Europe Forum
Asceneuron will participate in the 22nd Annual Biotech in Europe Forum for global partnering and investment (BEF), being held on...
-
Event
Asceneuron at the Latsis Symposium
Asceneuron will present at the Latsis Symposium 2022 organised by the EPFL from August 31st to September 2nd, 2022 in...
-
Event
Meet us at the ASBMB OGA Biology Conference!
Asceneuron will present at the ASBMB O-GlcNAc regulation of cellular physiology and pathophysiology conference on July 7–10, 2022 at the...
-
Press releases
Asceneuron Awarded Grant from The Michael J. Fox Foundation
Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies
